EUROCHIP PILOT STUDIES. Collection of detailed clinical information for specific tumours Describing and comparing care in representative samples of cancer.

Slides:



Advertisements
Similar presentations
High Resolution studies
Advertisements

Advanced breast cancer
Indicators to be included in the final list for EC Eurochip-3 WP6 meeting Brussels, September 9, 2011.
High Resolution data for rare cancers Annalisa Trama Fondazione IRCCS Istituto Nazionale dei Tumori, Milan (Italy ) WORKSHOP FOR A EUROPEAN HIGH RESOLUTION.
This presentation will ‘walk’ you through the pathway and guide you on how to use this tool.
Dr Andrea Micheli Descriptive Epidemiology and Health Planning Unit Fondazione IRCCS “Istituto Nazionale dei Tumori” Milan Public Health Programme EUROPEAN.
FROM EUROCHIP-1 TO EUROCHIP-2 EUROCHIP-2 - The action Public Health Program EUROPEAN COMMISSION: HEALTH & CONSUMER PROTECTION DIRECTORATE-GENERAL.
Cancer of Unknown Primary Dr Chris Jones Consultant Medical Oncologist North of England Cancer Network Annual Conference 20 September 2013.
ATLAS Steering Committee: 24 September 2005 Steering Committee meeting, 24 th September 2005 University of Oxford Examination Schools.
Tumor Markers Lecture one By Dr. Reem Sallam. Objectives  To briefly introduce cancers, their incidence, some common terms, and staging system.  To.
March 2002 Outcomes in thyroid cancer: what factors are important? Information Projects Team Outcomes in thyroid cancer: what factors are important? NYCRIS.
THE EUROCHIP PROJECTS Health Indicators for Health Indicators for Monitoring Cancer in Europe
EUROCHIP-2 the action Health Indicators for Monitoring Cancer in Europe Public Health Program EUROPEAN.
Matthew Kilmurry, M.D. St. Mary’s General Hospital Grand River Hospital.
Measures of disease frequency (I). MEASURES OF DISEASE FREQUENCY Absolute measures of disease frequency: –Incidence –Prevalence –Odds Measures of association:
Evaluation of Electronic Radiotherapy Data for Quality Checking Cancer Registry Data Colin Fox (NICR) Richard Middleton (NICR) Denise Lynd (BCH – COIS)
Breast cancer and medical second opinion
Discordance in Hormone Receptor and HER2 Status in Breast Cancer during Tumor Progression Lindstrom LS et al. Proc SABCS 2010;Abstract S3-5.
Clinical Relevance of HER2 Overexpression/Amplification in Patients with Small Tumor Size and Node-Negative Breast Cancer Curigliano G et al. J Clin Oncol.
Quality Cancer Data The Vital Role of Cancer Registrars in the Fight against Cancer Saves Lives.
Meta-analysis of trials of radiotherapy in DCIS Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)
EUROCHIP - EUROpean Cancer Health Indicators Project A project supported by the European Commission Andrea Micheli 1, Paolo Baili 1, Carmen Martinez 2,
SYNOPSIS OF THE PROTOCOL Title: Pregnancy Associated Breast Cancer (PABC); Prospective Data Registry in Saudi Arabia Sponsor: Oncology Department, King.
HSTAT1101: 27. oktober 2004 Odd Aalen
High Resolution Studies within the European Cancer Information System Cooperation with EPAAC Riccardo Capocaccia Istituto Superiore di Sanità (ISS), Italy.
Work Package 5 Information on centres of expertise for rare cancers WP leader: Sabine Siesling.
Objectives of Work Package 5 objectives for today Information on centres of expertise for rare cancers WP leader: Sabine Siesling.
Slides last updated: March 2015 CRC: STAGING. How colorectal cancer (CRC) is staged 1 Stage describes the extent of cancer, and is one of the most important.
The Carry-Over Effect of Adjuvant Zoledronic Acid: Comparison of 48- and 62-Month Analyses of ABCSG-12 Suggests the Benefits of Combining Zoledronic Acid.
Statistics about unknown primary tumors Riccardo Capocaccia National Centre for Epidemiology, Surveillance and Health Promotion Istituto Superiore di Sanità,
+ Clinical Decision on a Diagnostic Test Inna Mangalindan. Block N. Class September 15, 2008.
SYNCHRONOUS COLORECTAL AND LIVER RESECTION J Peter A Lodge MD FRCS HPB and Transplant Unit St James’s University Hospital Leeds LS9 7TF 2006 Association.
RARECARE project Data quality and supplementary information Granada, March 25 th 2009 Andalusian School of Public Health.
Generalized pairwise comparisons of prioritized outcomes Marc Buyse, ScD
1000 Lives Annual Report North of England Cancer Network Annual Conference 20 th September 2013.
Sandy Jones Public Health Advisor Centers for Disease Control and Prevention National Center for Chronic Disease Prevention and Health Promotion April.
Genetics and genomics for healthcare © 2014 NHS National Genetics and Genomics Education Centre Genetics and Genomics: Alert,
1 Lecture 6: Descriptive follow-up studies Natural history of disease and prognosis Survival analysis: Kaplan-Meier survival curves Cox proportional hazards.
Screening of diseases Dr Zhian S Ramzi Screening 1 Dr. Zhian S Ramzi.
Dr Andrea Micheli Descriptive Epidemiology and Health Planning Unit Fondazione IRCCS “Istituto Nazionale dei Tumori” Milan Public Health Programme EUROPEAN.
Supporting people with active and advanced disease Need better data collection Discussion at MDT – new diagnosis support Identify best practice Early palliative.
Unit 15: Screening. Unit 15 Learning Objectives: 1.Understand the role of screening in the secondary prevention of disease. 2.Recognize the characteristics.
Information Projects Team Radical therapies for prostate cancer October 2001 Radical therapies for prostate cancer Cathy Bennett Information Projects Manager.
Breast cancer affects 1 in 8 women during their lives. 1 Population Statistics.
Definition Signs & symptoms Treatment Root of the disease.
III. Measures of Morbidity: Morbid means disease. Morbidity is an important part of community health. It gives an idea about disease status in that community.
Screening – a discussion in clinical preventive medicine Galit M Sacajiu MD MPH.
The Cancer Registry of Norway Jan F Nygård Head of the IT-department.
Radical Prostatectomy versus Watchful Waiting in Early Prostate Cancer Anna Bill-Axelson, M.D., Lars Holmberg, M.D., Ph.D., Mirja Ruutu, M.D., Ph.D., Michael.
Screening Tests: A Review. Learning Objectives: 1.Understand the role of screening in the secondary prevention of disease. 2.Recognize the characteristics.
Melanoma Staging an update
Fig. 1 Frequency distribution of initial palliative treatment modalities used. EBRT, external beam radiotherapy. Initial palliative treatment modality.
Prepared by staff in Prevention and Cancer Control.
The Nurse View: Management of Pancreatic Cancer
A Paradigm Shift From One-Size-Fits-All to Tailor-Made Therapy for Metastatic Colorectal Cancer.
سرطان الثدي Breast Cancer
Dr T P E Wells 13 July 2018 Breast SSG Bath
West of England Genomics Medicine Centre Overview
Social & Environmental Determinants Risk & Protective Factors
Using CDK4/6 Inhibitors to Manage HR-Positive Metastatic Breast Cancer
Database and Projects Amit Patel.
A Better Solution For Cancer Patients With VTE?
Early Diagnosis Diagnostics Cancer Waits Survivorship South West Cancer Network 14 November 2014.
The Road to Quality Improvement in HER2-Positive Breast Cancer
Volume 383, Issue 9935, Pages (June 2014)
Recurrence pattern after initial treatment of brain metastases and cause of death. Recurrence pattern after initial treatment of brain metastases and cause.
Continuing Adjuvant Tamoxifen to 10 Years
SYNOPSIS OF THE PROTOCOL
Clinical characteristics at diagnosis of brain metastases.
Progression and survival analysis.
Presentation transcript:

EUROCHIP PILOT STUDIES

Collection of detailed clinical information for specific tumours Describing and comparing care in representative samples of cancer patients Proper inter-country and overtime survival comparisons, taking into account stage and diagnostic exams performed for staging Describing clinical events following diagnosis (local recurrences, distant metastases and the occurrence of a further primary tumour) Studying the time of progression of the disease Estimate survival after relapse Computing prevalence dividing the patients into those living in a disease-free status and those requiring care for a relapse of their cancer HIGH RESOLUTION STUDIES

Delay of cancer treatment indicator Compliance with guidelines indicator NEW QUESTIONS ON = + HIGH RESOLUTION STUDIES FORMS EUROCHIP PILOT STUDIES

INDICATORS ON TREATMENT DELAY – Breast cancer Decisions of Care & Treatment Domain Group

INDICATORS ON TREATMENT DELAY – Colon cancer Decisions of Care & Treatment Domain Group